Mast cells and basophils: Trojan horses of conventional lin- stem/progenitor cell isolates

Current Pharmaceutical Design

Volumn 17, Issue 34, 2011, Pages 3753-3771

  Heneberg, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Basophilia; Cancer initiating cells; CD16; CD203c; Degranulation; Histamine release; Mast cell infiltration; Neovascularization

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD24 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CELL MARKER; CHEMOTACTIC FACTOR; CYTOKINE; GLYCOPHORIN A; HISTAMINE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LACTATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ARTICLE; B LYMPHOCYTE; BASOPHIL; BONE MARROW CELL; CANCER GROWTH; CANCER THERAPY; CD34 SELECTION; CELL ACTIVATION; CELL ADHESION; CELL ISOLATION; CELL MEMBRANE; CELL POPULATION; CELL PROLIFERATION; DISEASE MODEL; EOSINOPHIL; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATORY CELL; MAST CELL; MELANOMA; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN CARCINOGENESIS; SOLID TUMOR; STEM CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 83455181348     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798357881     Document Type: Article

References (260)

1. Rous P. A transmissible avian neoplasm. (Sarcoma of the common fowl) by Peyton Rous, M.D., Experimental Medicine for Sept. 1, 1910, vol. 12, pp. 696-705. J Exp Med 1979; 150: 738-753.
2. Milford J, Duran-Reynals F. Growth of a chicken sarcoma virus in the chick embryo in the absence of neoplasia. Cancer Res 1943; 3: 578-584.
3. Stoker AW, Hatier C, Bissell MJ. The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia. J Cell Biol 1990; 111: 217-228.
4. Mintz B, Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 1975; 72: 3585-3589.
5. Bissell MJ, LaBarge MA. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005; 7: 17-23.
6. Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003; 63: 8573-8577.
7. Wu M, Pastor-Pareja JC, Xu T. Interaction between RasV12 and scribbled clones induces tumour growth and invasion. Nature 2010; 463: 545-548.
8. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM. The tumor microenvironment: A critical determinant of neoplastic evolution. Eur J Cell Biol 2003; 82: 539-548.
9. Overall CM, Kleifeld O. Tumor microenvironment - Opinion: Validating matrix metalloproteinases as drug target and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6: 227-239.
10. sted. Berlin: Verlag von August Hirschwald 1863.
11. Vande GF, Klein G. Advances in Cancer Research, Volume 93. 1st ed. London: Academic Press 2005.
12. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
14. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1: 119-150.
15. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
16. Kormelink TG, Abudukelimu A, Redegeld FA. Mast Cells as Target in Cancer Therapy. Curr Pharm Des 2009; 15: 1868-1878.
17. Schwartsburd PM. Chronic inflammation as inductor of pro-cancer microenvironment: Pathogenesis of dysregulated feedback control. Cancer Metastasis Rev 2003; 22: 95-102.
18. Westphal E. Über Mastzellen. In: Ehrlich P, Ed. Farbenanalytische Untersuchungen zur Histologie und Klinik des Blutes. Berlin: Hirschwald 1891; pp. 17-41.
19. Molin D, Edström A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodkin's lymphoma. Br J Haematol 2002; 119: 122-124.
20. Fisher ER, Paik SM, Rockette H, Jones J, Caplan R, Fisher B. Prognostic significance of eosinophils and mast cells in rectal cancer: Findings from the national surgical adjuvant breast and bowel project (protocol r-01). Hum Pathol 1989; 20: 159-163.
21. Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79: 451-455.
22. Strouch MJ, Cheon EC, Salabat MR, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 2010; 16: 2257-2265.
23. + T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113: 1387-1395.
24. Ibaraki T, Muramatsu M, Takai S, et al. The relationship of tryptase and chymase-positive mast cells to angiogenesis in stage I nonsmall cell lung cancer. Eur J Cardiothorac Surg 2005; 28: 617-621.
25. Imada A, Shijubo N, Kojima H, Abe S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 2000; 15: 1087-1093.
26. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000; 88: 2686-2892.
27. Tomita M, Matsuzaki Y, Onitsuka T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg 2000; 69: 1686-1690.
28. Blatner NR, Bonertz A, Beckhove P, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA 2010; 107: 6430-6435.
29. Iamaroon A, Pongsiriwet S, Jittidecharaks S, Pattanaporn K, Prapayasatok S, Wanachantararak S. Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med 2003; 32: 195-199.
30. Ribatti D, Vacca A, Ria R, et al. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 2003; 39: 666-674.
31. Ribatti D, Finato N, Crivellato E, et al. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol 2005; 193: 1961-1965.
32. Dabiri S, Huntsman D, Makretsov N, et al. The presence of stromal mast cells identifies a infset of invasive breast cancers with a favourable prognosis. Mod Pathol 2004; 17: 690-695.
33. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005; 23: 8959-8967.
34. Rudolph MI, Boza Y, Yefi R, et al. The influence of mast cell mediators on migration of sw756 cervical carcinoma cells. J Pharmacol Sci 2008; 106: 208-218.
35. Starkey JR, Crowle PK, Taubenberger S. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988; 42: 48-52.
36. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007; 13: 1211-1218.
37. Coussens LM, Raymond WW, Bergers G, et al. Inflamatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-1397.
38. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-490.
39. Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003; 101: 3386-3390.
40. Füreder W, Schernthaner GH, Ghannadan M, et al. Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Invest 2001; 31: 894-901.
41. Shibata K, Watanabe M, Yano H, Matsuzaki M, Funai N, Sano M. Importance of basophilia in haematopoietic disorders. Haematologia (Budapest) 1998; 29: 241-253.
42. Wimazal F, Baumgartner C, Sonneck K, et al. Mixed basophil/ eosinophil transformation in chronic myelomonocytic leukemia. Eur J Clin Invest 2008; 38: 447-445.
43. Wimazal F, Germing U, Kundi M, et al. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer 2010; 116: 2372-2381.
44. Denburg JA, Browman G. Prognostic implications of basophil differentiation in chronic myeloid leukemia. Am J Hematol 1988; 27: 110-114.
45. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-1446.
46. Gomez GA, Sokal JE, Walsh D. Prognostic features at diagnosis of chronic myelocytic leukemia. Cancer 1981; 47: 2470-2477.
47. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.
48. Steegmann JL, Odriozola J, Rodriguez-Salvanés F, et al. Stage, percentage of basophils at diagnosis, hematologic response within 6 months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-α. Results of the CML89 trial of the Spanish Collaborative Group on interferon- α 2a and CML. Haematologica 1999; 84: 978-987.
49. Anthony HM. Blood basophils in lung cancer. Br J Cancer 1982; 45: 209-216.
50. Gracheva ZA, Babakova SV, Gorodilova VV, Sokova II. [State of blood basophilic granulocytes in the estimation of sensitisation of patients with stomach neoplasm]. Vopr Onkol 1976; 22(10): 19-21. (in Russian)
51. Sergeev SI, Gracheva ZA, Bergut FA, Sokova II. [Degranulation and intracellular heparin of basophilic granulocytes in patients with stomach cancer]. Sov Med 1977; 41(2): 29-33. (in Russian)
52. Bishara S, Griffin A, Cargill A, et al. Pre-treatment white blood cell inftypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2008; 138: 71-75.
53. Cramer W, Simpson WL. Mast cells in experimental skin carcinogenesis. Cancer Res 1944; 4: 601-616.
54. Parmley RT, Spicer SS, Wright NJ. The ultrastructural identification of tissue basophils and mast cells in Hodgkin'sss disease. Lab Invest 1975; 32: 469-475.
55. Kimura S. Mast cells in solitary glomus tumors: a possible algogenic role. Acta Derm Venereol 1979; 59: 415-419.
56. Hartveit F. Mast cells and metachromasia in human breast cancer: their occurence, significance and consequence: a preliminary report. J Pathol 1981; 134: 7-11.
57. Black MM, Leis HP Jr. Cellular responses to autologous breast cancer tissue. Correlation with stage and lymphoreticuloendothelial reactive. Cancer 1971; 28: 263-273.
58. Galli SJ, Colvin RB, Orenstein NS, Dvorak AM, Dvorak HF. Patients without basophils. Lancet 1977; 310: 409.
59. Tanooka H, Kitamura Y, Sado T, Tanaka K, Nagase M, Kondo S. Evidence for involvement of mast cells in tumor suppression in mice. J Natl Cancer Inst 1982; 69: 1305-1309.
60. Galli SJ, Dvorak HF, Churchill WH, et al. Basophil-tumor cell interactions in vitro. Fed Proc 1977; 36: 1324.
61. Kuroda E, Ho V, Ruschmann J, et al. SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J Immunol 2009; 183: 3652-3660.
62. Sullivan BM, Liang HE, Bando JK. Genetic analysis of basophil function in vivo. Nat Immunol 2011; 12: 527-535.
63. Heneberg P, Dráberová L, Bambousková M, Pompach P, Dráber P. Down-regulation of protein-tyrosine phosphatases activates an immune receptor in the absence of its translocation into lipid rafts. J Biol Chem 2010; 285: 12787-1802.
64. Heneberg P, Dráber P. Regulation of Cys-based protein tyrosine phosphatases via reactive oxygen and nitrogen species in mast cells and basophils. Curr Med Chem 2005; 12: 1859-1871.
65. Rao KN, Brown MA. Mast cells. Ann N Y Acad Sci 2008; 1143: 83-104.
66. Lin AM, Rubin CJ, Khandpur R, et al. Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis. J Immunol 2011; online first, doi: 10.4049/jimmunol.1100123.
67. Ochensberger B, Daepp GC, Rihs S, Dahinden CA. Human blood basophils produce interleukin-13 in response to IgE-receptordependent and -independent activation. Blood 1996; 88: 3028-3037.
68. Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993; 177: 605-611.
69. Azuma YT, Nakajima H, Takeuchi T. IL-19 as a potential therapeutic in autoimmune and inflammatory diseases. Curr Pharm Des 2011; 17(34): 3776-3780.
70. Saadoun D, Terrier B, Cacoub P. Interleukin-25: key regular of inflammatory and autoimmune diseases. Curr Pharm Des 2011; 17(34): 3781-3785.
71. Gilfillan AM, Tkaczyk C. Integrated signaling pathways for mastcell activation. Nat Rev Immunol 2006; 6: 218-230.
72. Marietta EV, Weis JJ, Weis JH. CD28 expression by mouse mast cells is modulated by lipopolysaccharide and outer surface protein A lipoprotein from Borrelia burgdorferi. J Immunol 1997; 159: 2840-2848.
73. Oki T, Kitaura J, Eto K, et al. Integrin αIIbβ3 induces the adhesion and activation of mast cells through interaction with fibrinogen. J Immunol 2006; 176: 52-60.
74. Miyazaki D, Nakamura T, Toda M, et al. Macrophage inflammatory protein-1α as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J Clin Invest 2005; 115: 434-442.
75. Jolly PS, Bektas M, Olivera A, et al. Transactivation of sphingosine- 1-phosphate receptors by FcεRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 2004; 199: 959-970.
76. Heneberg P. [Molecular aspects of anaphylactic reactions]. Alergie 2008; 10: 190-196. (in Czech)
77. Heneberg P, Lebduška P, Dráberová L, Korb J, Dráber P. Topography of plasma membrane microdomains and its consequences for mast cell signaling. Eur J Immunol 2006; 36: 2795-2806.
78. Tolarová H, Dráberová L, Heneberg P, Dráber P. Involvement of filamentous actin in setting the threshold degranulation in mast cells. Eur J Immunol 2004; 34: 1627-1636.
79. Katz HR, Vivier E, Castells MC, McCormick MJ, Chambers JM, Austen KF. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when colligated with the high-affinity Fc receptor for IgE. Proc Natl Acad Sci USA 1996; 93: 10809-10814.
80. Erdei A, Andreev S, Pecht I. Complement peptide C3A inhibits IgE-mediated triggering of rat mucosal mast cells. Int Immunol 1995; 7: 1433-1439.
81. Abramson J, Pecht I. Crustering the mast cell function-associated antigen (MAFA) leads to tyrosine phosphorylation of p62Dok and SHIP and affects RBL-2H3 cell cycle. Immunol Lett 2002; 82: 23-28.
82. Abramson J, Pecht I. Regulation of the mast cell response to the type 1 Fcε receptor. Immunol Rev 2007; 217: 231-254.
83. Qu Z, Huang X, Ahmadi P, et al. Synthesis of basic fibroblast growth factor by murine mast cells. Regulation by transforming growth factor beta, tumor necrosis factor alpha, and stem cell factor. Int Arch Allergy Immunol 1998; 115: 47-54.
84. Grützkau A, Krüger-Krasagakes S, Baumeister H, et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 1998; 9: 875-884.
85. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. Nature 1982; 297: 229-231.
86. Jorpes JE. Heparin: a mucopolysaccharide and an active antithrombotic drug. Circulation 1959; 19: 87-91.
87. Okayama Y, Ono Y, Nakazawa T, Church MK, Mori M. Human skin mast cells produce TNF-α by infstance P. Int Arch Allergy Immunol 1998; 117(suppl 1): 48-51.
88. Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest 2004; 114: 1317-1325.
89. Clinton M, Long WF, Williamson FB, Duncan JI, Thompson WD. Effect of the mast cell activator compound 48/80 and heparin on angiogenesis in the chick chorioallantoic membrane. Int J Microcirc Clin Exp 1988; 7: 315-326.
90. Ribatti D, Crivellato E, Candussio L, et al. Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane. Clin Exp Allergy 2001; 31: 602-608.
91. Norrby K, Jakobsson A, Sorbo J. Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol Incl Mol Pathol 1986; 52: 195-206.
92. Heissig B, Rafii S, Akiyama H, et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 2005; 202: 739-750.
93. Hebda PA, Collins MA, Tharp MD. Mast cell and myofibroblast in wound healing. Dermatol Clin 1993; 11: 685-696.
94. Shin K, Nigrovic PA, Crish J, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009; 182: 647-656.
95. Shin K, Nigrovic PA, Crish J, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009; 182: 647-656.
96. Huang B, Lei Z, Zhang GM, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008; 112: 1269-1279.
97. Stevens RL, Adachi R. Protease-proteoglycan complexes of mouse and human mast cells and importance of their β-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev 2007; 217: 155-167.
98. Pejler G, Rönnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 2010; 115: 4981-4990.
99. Kielty CM, Lees M, Shuttleworth CA, Woolley D. Catabolism of intact type VI collagen microfibrils: susceptibility to degradation by serine proteinases. Biochem Biophys Res Commun 1993; 191: 1230-1236.
100. Fajardo I, Pejler G. Human mast cell β-tryptase is a gelatinase. J Immunol 2003; 171: 1493-1499.
101. Banovac K, Banovac F, Yang J, Koren E. Interaction of osteoblasts with extracellular matrix: effect of mast cell chymase. Proc Soc Exp Biol Med 1993; 203: 221-235.
102. Kofford MW, Schwartz LB, Schechter NM, Yager DR, Diegelmann RF, Graham MF. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem 1997; 272: 7127-7131
103. Tchougounova E, Pejler G, Abrink M. The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue: a role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J Exp Med 2003; 198: 423-431.
104. Vartio T, Seppa H, Vaheri A. Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J Biol Chem 1981; 256: 471-477.
105. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of promatrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-9296.
106. Fang KC, Raymond WW, Lazarus SC, Caughey GH. Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. J Clin Invest 1996; 97: 1589-1596.
107. Algermissen B, Hermes B, Feldmann-Boeddeker I, Bauer F, Henz BM. Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars. Exp Dermatol 1999; 8: 193-198.
108. Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 1991; 88: 493-499.
109. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3: 895-904.
110. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: Angiogenesis, tissue remodeling and immune-modulation. Biochim Biophys Acta 2009; 1796: 19-26.
111. Imaizumi T, Louis J, Bailly C, Cicurel L, Petchot JP, Dubertret L. Effect of human basic fibroblast growth factor on fibroblast proliferation, cell volume, collagen lattice contraction: in comparison with acidic type. J Dermatol Sci 1996; 11: 134-141.
112. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007; 178: 4222-4229.
113. Shin K, Watts GF, Oettgen HC, et al. Mouse mast cell tryptase mMCP-6 is a critical link between adaptive and innate immunity in the chronic phase of Trichinella spiralis infection. J Immunol 2008; 180: 4885-4891.
114. Blanchet MR, Maltby S, Haddon DJ, Merkens H, Zbytnuik L, McNagny KM. CD34 facilitates the development of allergic asthma. Blood 2007; 110: 2005-2012.
115. Hamilton MJ, Sinnamon MJ, Lyng GD, et al. Essential role for mast cell tryptase in acute experimental colitis. Proc Natl Acad Sci USA 2011; 108: 290-295.
116. Nakamura Y, Kambe N, Saito M, et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticarial. J Exp Med 2009; 206: 1037-1046.
117. Sayed BA, Christy AL, Walker ME, Brown MA. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: A role for neutrophil recruitment? J Immunol 2010; 184: 6891-900.
118. Biedermann T, Kneilling M, Mailhammer R, et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000; 192: 1441-1452.
119. Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001; 108: 1151-1158.
120. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 1996; 381: 77-80.
121. Zhang Y, Ramos BF, Jakschik B. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 1992; 258: 1957-1979.
122. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997-1002.
123. Gounaris E, Blatner NR, Dennis K, et al. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 2009; 69: 5490-5497.
124. + regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008; 29: 771-81.
125. Kennedy Norton S, Barnstein B, Brenzovich J, et al. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 2008; 180: 2848-2854.
126. de Vries VS, Wasiuk A, Bennett KA, et al. Mast cell degranulation breaks peripheral tolerance. Am J Transplant 2009; 9: 2270-2780.
127. Piconese S, Gri G, Tripodo C, et al. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009; 114: 2639-48.
128. Kashyap M, Thornton AM, Norton SK, et al. Cutting edge: CD4 T cell-mast cell interactions alter IgE receptor expression and signaling. J Immunol 2008; 180: 2039-2043.
129. McLachlan JB, Hart JP, Pizzo SV, et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol 2003; 4: 1199-1205.
130. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. J Immunol 2006; 176: 4102-4112.
131. Nakae S, Suto H, Iikura M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006; 176: 2238-2248.
132. Vincent-Schneider H, Thery C, Mazzeo D, Tenza D, Raposo G, Bonnerot C. Secretory granules of mast cells accumulate mature and immature MHC class II molecules. J Cell Sci 2001; 114: 323-334.
133. Tripodo C, Gri G, Piccaluga PP, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol 2010; 177: 792-802.
134. Skokos D, La Panse S, Villa I, et al. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol 2001; 166: 868-876.
135. Tkaczyk C, Frandji P, Botros HG, et al. Mouse bone marrowderived mast cells and mast cell lines constitutively produce B cell growth and differentiation activities. J Immunol 1996; 157: 1720-1728.
136. Tkaczyk C, Villa I, Peronet R, David B, Chouaib S, Mécheri S. In vitro and in vivo immunostimulatory potential of bone marrowderived mast cells on B- and T-lymphocyte activation. J Allergy Clin Immunol 2000; 105: 134-142.
137. Inamura N, Mekori YA, Bhattacharyya SP, Bianchine PJ, Metcalfe DD. Induction and enhancement of FcεRI-dependent mast cell degranulation following coculture with activated T cells: dependency on ICAM-1-and leukocyte function-associated antigen (LFA)-1- mediated heterotypic aggregation. J Immunol 1998; 160: 4026.
138. Skokos D, Botros HG, Demeure C, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003; 170: 3037-3045.
139. Yoshikawa T, Imada T, Nakakubo H, Nakamura N, Naito K. Rat mast cell protease-1 enhances immunoglobulin E production byentiation toward IgA-secreting plasma cells. Blood 2010; 115: 2810-2817.
140. Tønnesen H, Knigge U, Bülow S, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988; 2: 990-992.
141. Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol 1988; 24: 161-167.
142. Yang XD, Ai W, Asfaha S, et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med 2011; 17: 87-95.
143. Yang XD, Wang TC. Reply to Antitumor properties of histamine in vivo. Nat Med 2011; 17: 537-8.
144. Burtin C, Scheinmann P, Salomon JC, Lespinats G, Canu P. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer 1982; 45: 54-60.
145. Tatsuta M, Iishi H, Ichii M, Noguchi S, Yamamura H, Taniguchi H. Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N'-nitronitrosoguanidine. J Natl Cancer Inst 1986; 76: 277-281.
146. Hellstrand K. Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 2002; 29: 35-40.
147. Suonio E, Tuomisto L, Alhava E. Effects of histamine, H1, H2 and Hic receptor antagonists and α-fluoromethylhistidine on the growth of human colorectal cancer in the infrenal capsule assay. Agents Actions 1994; 41: C118-C20.
148. Dellarovere F, Broccio G, Granata A, Fimiani V. In-vivo experimental demonstration that hyperhistaminism counteracts tumorgrowth. Oncol Rep 1994; 1: 175-177.
149. Martner A, Thorén FB, Aurelius J, Söderholm J, Brune M, Hellstrand K. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Epert Rev Hematol 2010; 3: 381-391.
150. Thoren FB, Aurelius J, Martner A. Antitumor properties of histamine in vivo. Nat Med 2011; 17: 537.
151. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006; 108: 88-96.
152. Conti P, Castellani ML, Kempuraj S, et al. Role of mast cells in tumor growth. Ann Clin Lab Sci 2007; 37: 315-322.
153. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol 2001; 115: 514-521.
154. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-241.
155. Schittek A, Issa HA, Stafford JH, Young D, Zwilling B, James AG. Growth of pulmonary metastases of B16 melanoma in mast cellfree mice. J Surg Res 1985; 38: 24-28.
156. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1α and 6 and tumor necrosis factor- α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991; 96: 180-185.
157. Dabbous MK, Walker R, Haney L, Carter LM, Nicolson GL, Woolley DE. Mast cells and matrix degradation at sites of tumour invasion in rat mammary adenocarcinoma. Br J Cancer 1986; 54: 459-465.
158. Samoszuk M, Kanakubo E, Chan JK. Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin inferferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer 2005; 5: 121-131.
159. Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 2008; 27: 5886-5893.
160. Hedström G, Berglund M, Molin D, et al. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2007; 138: 68-71.
161. Rajput AB, Turbin DA, Cheang MC, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat 2008; 107: 249-257.
162. Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 2008; 29: 880-886.
163. Nielsen JS, McNagny KM. CD34 is a Key Regulator of Hematopoietic Stem Cell Trafficking to Bone Marrow and Mast Cell Progenitor Trafficking in the Periphery. Microcirculation 2009; 16: 487-496.
164. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
165. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis III; A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133: 157-165.
166. + marrow cells engraft lethally irradiated baboons. J Clin Invest 1988; 81: 951-955.
167. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
168. Gangenahalli GU, Singh VK, Verma YK, et al. Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev 2006; 15: 305-313.
169. Drew E, Merkens H, Chelliah S, Doyonnas R, McNagny KM. CD34 is a specific marker of mature murine mast cells. Exp Hematol 2002; 30: 1211-1218.
170. Drew E, Merzaban JS, Seo W, Ziltener HJ, McNagny KM. CD34 and CD43 inhibit mast cell adhesion and are required for optimal mast cell reconstitution. Immunity 2005; 22: 43-57.
171. Suzuki A, Andrew DP, Gonzalo JA, et al. CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein. Blood 1996; 87: 3550-3562.
172. Gounaris E, Erdman SE, Restaino C, et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 2007; 104: 19977-19982.
173. + hemopoietic progenitor cells in atopic infjects. Am J Respir Cell Mol Biol 1996; 15: 645-654.
174. Han X, Jorgensen JL, Brahmandam A, et al. Immunophenotypic study of basophils by multiparameter flow cytometry. Arch Pathol Lam Med 2008; 132: 813-819.
175. Welker P, Krämer S, Groneberg DA, et al. Increased mast cell number in human hypertensive nephropathy. Am J Physiol Renal Physiol 2008; 295: F1103-F1109.
176. Bachmann MF, Barner M, Kopf M. CD2 sets quantitative tresholds in T cell activation. J Exp Med 1999; 190: 1383-1392.
177. Matsui T, Connolly JE, Michnevitz M, et al. CD2 distinguishes two infsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182: 6815-6823.
178. Valent P, Sotlar K, Horny H-P. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30- positive neoplasms. Leuk Lymphoma 2011; on-line first, DOI: 10.3109/10428194.2010.550072.
179. Yoshida M, Nishikawa Y, Yamamoto Y, et al. Mast cell leukemia with rapidly progressing portal hypertension. Pathol Int 2009; 59: 817-822.
180. van Daele PL, Beukenkamp BS, Geertsma-Kleinekoort WM, et al. Immunophenotyping of mast cells: a sensitive and specific diagnostictool for systemic mastocytosis. Neth J Med 2009; 67: 142-146.
181. Baumgartner C, Sonneck K, Krauth MT, et al. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest 2008; 38: 326-335.
182. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growthinhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007; 92: 1451-1459.
183. Krauth MT, Majlesi Y, Florian S, et al. Cell surface membrane antigen phenotype of human gastrointestinal mast cells. Int Arch Allergy Immunol 2005; 138: 111-120.
184. Noack F, Sotlar K, Notter M, Thiel E, Valent P, Horny H-P. Aleukemic mast cell leukemia with abnormal immunophenotype and ckit mutation D816V. Leuk Lymphoma 2004; 45: 2295-2302.
185. Beil WJ, Füreder W, Wiener H, et al. Phenotypic and functional characterization of mast cells derived from renal tumor tissues. Exp Hematol 1998; 26: 158-169.
186. Schernthaner GH, Hauswirth AW, Baghestanian M, et al. Detection of differentiation- and activation-linked cell surface antigens on cultured mast cell progenitors. Allergy 2005; 60: 1248-1255.
187. Medina-Tamayo J, Ibarra-Sánchez A, Padilla-Trejo A, González- Espinosa C. IgE-dependent sensitization increases responsiveness to LPS but does not modify development of endotoxin tolerance in mast cells. Inflamm Res 2011; 60: 19-27.
188. Ikeda T, Funaba M. Altered function of murine mast cells in response to lipopolysaccharide and peptidoglycan. Immunol Lett 2003; 88: 21-26.
189. McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activation of murine mast cells. J Leukoc Biol 2001; 70: 977-984.
190. Lin TY, Thomas R, Tsai PC, Breen M, London CA. Generation and characterization of novel canine malignant mast cell line CL1. Vet Immunol Immunopathol 2009; 127: 114-124.
191. Escribano L, Orfao A, Villarrubia J, et al. Immunophenotypic characterization of human bone marrow mast cells: A flow cytometric study of normal and pathological bone marrow samples. Anal Cell Pathol 1998; 16: 151-159.
192. Lin TY, London CA. A functional comparison of canine and murine bone marrow derived cultured mast cells. Vet Immunol Immunopathol 2006; 114: 320-334.
193. Füderer W, Bankl HC, Toth J, et al. Immunophenotypic and functional characterization of human tonsillar mast cells. J Leukoc Biol 1997; 61: 592-529.
194. Sperr WR, Bankl HC, Mundigler G, et al. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood 1994; 84: 3876-3884.
195. Reimer JM, Magnusson S, Juremalm M, Nilsson G, Hellman L, Wernersson S. Isolation of transcriptionally active umbilical cord blood-derived basophils expressing FcεRI, HLA-DR and CD203c. Allergy 2006; 61: 1063-1070.
196. Passante E, Frankish N. Deficiencies in elements involved in TLR4-receptor signalling in RBL-2H3 cells. Inflamm Res 2010; 59: S185-S186.
197. Bieneman, Chichester KL, Chen YH, Schroeder JT. Toll-like receptor 2 ligands activate human basophils for both IgE-dependent and IgE-independent secretion. J Allergy Clin Immunol 2005; 115: 295-301.
198. Klaassen RJ, Ouwehand WH, Huizinga TW, Engelfriet CP, von dem Borne AE. The Fc-receptor III of cultured human monocytes: structural similarity with FcRIII of natural killer cells and role in the extracellular lysis of sensitized erythrocytes. J Immunol 1990; 144: 599-606.
199. Anderson P, Caliguiri M, O'Brian C, Manley T, Ritz J, Scholssman SF. FcγRIII (CD16) is included in the ζ NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci USA 1990; 87: 2274-2278.
200. Kim HY, Kim S, Chung DH. FcγRIII engangement provides activating signals to NKT cells in antibody-induced joint inflammation. J Clin Invest 2006; 116: 2484-92.
201. Meknache N, Jönsson F, Laurent J, Guinnepain MT, Daëron M. Human basophils express the glycosylphosphatidylinositolanchored low-affinity IgG receptor FcγRIIIB (CD16B). J Immunol 2009; 182: 2542-2550.
202. Takahashi K, Takata M, Suwaki T, et al. New flow cytometric method for surface phenotyping basophils from peripheral blood. J Immunol Methods 1993; 162: 17-21.
203. Han K, Kim Y, Lee J, et al. Human basophils express CD22 without expression of CD19. Cytometry 1999; 37: 178-183.
204. Tsujimura Y, Obata K, Mukai K, et al. Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-Emediated systemic anaphylaxis. Immunity 2008; 28: 581-589.
205. Malbec O, Daëron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev 2007; 217: 206-221.
206. Anselmino LM, Perussia B, Thomas LL. Human basophils selectively express the FcγRII (CDw32) inftype of IgG receptor. J Allergy Clin Immunol 1989; 84: 907-914.
207. Escribano L, Díaz-Agustín B, Núñez R, Prados A, Rodríguez R, Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 2002; 127: 127-132.
208. Andrásfalvy M, Prechl J, Hardy T, Erdei A, Bajtay Z. Mucosal type mast cells express complement receptor type 2 (CD21). Immunol Lett 2002+ 82: 29-34.
209. Gommerman JL, Oh DY, Zhou X, et al. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol 2000; 165: 6915-6921.
210. Hernández-Campo PM, Almeida J, Matarraz S, de Santiago M, Sánchez ML, Orfao A. Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B Clin Cytom 2007; 72: 34-42.
211. Geoffrey R, Jia S, Kwitek AE, et al. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 2006; 177: 7275-7286.
212. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-xL. Hum Pathol 2001; 32: 545-552.
213. Ghannadan M, Hauswirth AW, Schernthaner GH, et al. Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol 2002; 127: 299-307.
214. Blom T, Nilsson G, Sundström C, Nilsson K, Hellman L. Characterization of a human basophil-like cell line (LAMA-84). Scand J Immunol 1996; 44: 54-61.
215. Nilsson G, Blom T, Kusche-Gullberg M, et al. Phenotypic characterization of the human mast-cell line HMC-1. Scand J Immunol 1994; 39: 489-498.
216. Siebert PD, Fukuda M. Molecular cloning of a human glycophorin B cDNA: nucleotide sequence and genomic relationship to glycophorin A. Proc Natl Acad Sci USA 1987; 84: 6735-6739.
217. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004; 28: 1319-1325.
218. Hamann K, Haas N, Grabbe J, Welker P, Czernetzki BM. Two novel mast cell phenotypic markers, monoclonal antibodies Ki- MC1 and Ki-M1P, identify distinct mast cell inftypes. Br J Dermatol 1995; 133: 547-552.
219. Hennersdorf F, Florian S, Jakob A, et al. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Research 2005; 15. 325-335.
220. Lebduška P, Korb J, Tomová M, Heneberg P, Dráber P. Topography of signaling molecules as detected by electron microscopy on plasma membrane sheets isolated from non-adherent mast cells. J Immunol Methods 2007; 328: 139-151.
221. Kalesnikoff J, Rios EJ, Chen CC, et al. RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proc Natl Acad Sci USA 2006; 103: 2659-2664.
222. + stem cell recovery after positive selection of "overloaded" immunomagnetic columns. Stem Cells Dev 2005; 14: 740-743.
223. Kim JM, Oh YK, Kim YJ, Youn J, Ahn MJ. Escherichia coli upregulates proinflammatory cytokine expression in granulocyte/ macrophage lineages of CD34 stem cells via p50 homodimeric NF-κB. Clin Exp Immunol 2004; 137: 341-350.
224. + cells via mitogen- activated protein kinase-dependent and NF-κB-independent pathways. Int Immunol 2005; 17: 1525-1531.
225. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004; 173: 531-541.
226. Möller A, Lippert U, Lessmann D, et al. Human mast cells produce IL-8. J Immunol 1993; 151: 3261-3566.
227. Oliver JM, Tarleton CA, Gilmartin L, et al. Reduced FcεRImediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010; 151: 275-284.
228. Schroeder JT, Chen Y, Bieneman AP, Chichester KL, Siekierski E. Relative expression of toll-like receptor (TLR)-9 protein in human basophils vs. Plasmacytoid dendritic cells (PDC). J Allergy Clin Immunol 2004; 113: S102.
229. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 2008; 135: 437-448.
230. Staser K, Yang F-C, Clapp DW. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells. Curr Opin Hematol 2010; 17. 287-293.
231. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932.
232. Thomas DM, Fox J, Haston CK. Imatinib therapy reduces radiation- induced pulmonary mast cell influx and delays lung disease in the mouse. Int J Radiat Biol 2010; 86: 436-444.
233. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006; 107: 345-351.
234. Juurikivi A, Sandler C, Lindstedt KA, et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 2005; 64: 1126-1131.
235. Yoshida C, Takeuchi M, Tsuchiyama J, Sadahira Y. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-α. Intern Med 2009; 48: 1973-1978.
236. Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006; 6: 478-483.
237. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369: 1731-41.
238. Pittoni P, Piconese S, Tripodo C, Colombo MP. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 2011; 30: 757-69.
239. Herbst RS, Oh Y, Wagle A, Lahn M. Enzastaurin, a protein kinase Cβ-selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res 2007; 13: 4641-4646.
240. Nechushtan H, Leitges M, Cohen C, Kay G, Razin E. Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cβ. Blood 2000; 95: 1752-1727.
241. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C βII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus- specific fashion. J Biol Chem 2004; 279: 47720-47725.
242. Galinsky DS, Nechushtan H. Mast cells and cancer-no longer just basic science. Crit Rev Oncol Hematol 2008; 68: 115-30.
243. Fischer M, Harvima IT, Carvalho RF, et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation- independent chemokine secretion. J Clin Invest 2006; 116: 2748-2756.
244. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764-2769.
245. Schnell R, Borchmann P. SGN-30 (Seattle genetics). Curr Opin Mol Ther 2006; 8: 164-172.
246. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25: 5410-5417.
247. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007; 9: 115-119.
248. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol 2008; 20: 19-24.
249. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474-5483.
250. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834-848.
251. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem 2009; 16: 706-733.
252. Strunk D, Rohde E, Lanzer G, Linkesch W. Phenotypic characterization and preclinical production of human lineage-negative cells for regenerative stem cell therapy. Transfusion 2005; 45: 315-326.
253. Heinemann A, Sturm GJ, Ofner M, et al. Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils. J Allergy Clin Immunol 2005; 116: 820-826.
254. Li L, Li Y, Reddel SW, et al. Identification of basophilic cells that express mast cell granule proteases in the peripheral blood of asthma, allergy, and drug-reactive patients. J Immunol 1998; 161: 5079-5086.
255. Nguyen D, Diamond LW, Braylan RC. Flow cytometry in hematopathology: A visual approach to data analysis and interpretation. 2nd ed. Totowa: Humana Press 2007.
256. Agis H, Füreder W, Bankl HC, et al. Comparative phenotypic analysis of human mast cells, blood monocytes and blood basophils: Dissection of three distinct myeloid cell lineages. Immunology 1996; 87: 535-543.
257. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: Biochemical and functional characterization. Adv Immunol 1992; 52: 333-423.
258. Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA. Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)- mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 1997; 186: 313-323.
259. Heneberg P. Supposed steep increase in publications on cruciate ligament and other topics. Eur J Orthop Surg Traumatol 2011; 21: 401-405.
260. Heneberg P. On bibliometric analysis of chinese research on cyclization, MALDI-TOF, and antibiotics: methodical concerns. J Chem Inf Model 2011; 51: 1-2.